Supernus Pharmaceuticals (0LB2) Income Statement
Supernus Pharmaceuticals Income Statement
Last quarter (Q3 2026), Supernus Pharmaceuticals's total revenue was $226.77M, an increase of 18.05% from the same quarter last year. In Q3, Supernus Pharmaceuticals's net income was $20.91M. See Supernus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 718.95M | $ 661.82M | $ 607.52M | $ 667.24M | $ 579.77M | |
| $ 644.39M | $ 583.91M | $ 523.74M | $ 580.02M | $ 504.71M | |
| $ 681.25M | $ 502.25M | $ 529.01M | $ 533.89M | $ 418.69M | |
| Depreciation and Amortization | $ 91.56M | $ 80.41M | $ 84.86M | $ 85.54M | $ 32.59M |
| $ 42.53M | $ 178.28M | $ 90.04M | $ 153.36M | $ 129.19M | |
| $ -36.86M | $ 81.67M | $ -5.27M | $ 46.12M | $ 86.03M | |
| $ -12.17M | $ 16.20M | $ 8.04M | $ 14.62M | $ -12.85M | |
| $ -49.03M | $ 97.87M | $ 2.77M | $ 60.74M | $ 73.17M | |
| $ -38.55M | $ 73.86M | $ 1.32M | $ 60.71M | $ 53.42M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.68 | $ 1.34 | $ 0.02 | $ 1.13 | $ 1.01 |
| Diluted EPS | $ -0.68 | $ 1.32 | $ 0.02 | $ 1.04 | $ 0.98 |
| Weighted Average Shares Outstanding | 56.45M | 55.10M | 54.54M | 53.67M | 53.10M |
| Weighted Average Shares Outstanding (Diluted) | 56.45M | 55.96M | 55.51M | 61.68M | 54.36M |
Currency in USD